Clinical trials: Pharmacokinetic Profile
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Pulmonary Disease, Chronic Obstructive
Study of GSK961081 in Healthy Volunteer Subjects
GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans.
- Trial name
- NCT00887406
- Testing
- GSK961081 15mcg SD, GSK961081 3mcg SD, GSK961081 50mcg SD
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Smoking
Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L
The purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, and the safety and tolerability of the nicotine-containing aerosol delivered by Platform 3 Liquid…
- Trial name
- NCT02532374
- Testing
- Nicorette® inhalator, P3L
- Where
- New Zealand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Advanced Solid Tumors
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
The research project is testing this potential new medication for advanced solid tumours. This research project is being done to get more information about the study drug (XNW7201).
- Trial name
- NCT03901950
- Testing
- XNW7201 tablets
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Evopoint Biosciences Inc.
Psoriasis Vulgaris
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects
This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive…
- Trial name
- NCT03819218
- Testing
- MC2-01 cream
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 7 people
- Sponsor
- MC2 Therapeutics
Healthy
Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers
The objective of the study is to determine the safety and pharmacokinetics of a 7 day course of oral mibefradil given four times a day in healthy volunteers.
- Trial name
- NCT01550458
- Testing
- mibefradil
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cavion, Inc.
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects
The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic…
- Trial name
- NCT06449859
- Testing
- TQC2938 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Pain
Naproxen Sodium ER Pharmacokinetic Study
To determine the pharmacokinetic profile of the investigational product following dosing under fed conditions.
- Trial name
- NCT00818415
- Testing
- Naproxen sodium ER (BAYH6689), Commercial Naproxen (Aleve, BAYH6689)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Prostatic Neoplasms
PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers
This is a Phase I, single centre, prospective, randomized, alternating panels, ascending doses with interspersed placebo, double-blind, crossover trial.
- Trial name
- NCT04839120
- Testing
- MDPK67b
- Where
- Switzerland
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Med Discovery SA
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Healthy Volunteers
A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, PD, safety and immunogenicity profile of MB09 with EU/US-Xgeva® in healthy male subjects.
- Trial name
- NCT05299073
- Testing
- MB09, US-sourced Xgeva, EU-sourced Xgeva
- Where
- Poland
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.
Advanced Solid Tumor
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with…
- Trial name
- NCT06682780
- Testing
- LM-2417, Docetaxel, Toripalimab/Tirelizumab
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LaNova Medicines Limited
Healthy
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection in healthy subjects.
- Trial name
- NCT02781753
- Testing
- Human Serum Albumin/interferon alpha2b, Peginterferon 180 μg single dose S.C.
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Tianjin SinoBiotech Ltd.
Type 2 Diabetes Mellitus
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
This is a phase I, open-label, fixed-sequence study in healthy Chinese subjects, performed at a single study centre. Cohort A will assess the Pharmacokinetic (PK) profile of rongliflozin when administered alone and the…
- Trial name
- NCT05497674
- Testing
- Rongliflozin, Rifampin, Probenecid
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Solid Tumor, Advanced Solid Tumor
First in Human Study of M4344 in Participants With Advanced Solid Tumors
The purpose of this study was to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced…
- Trial name
- NCT02278250
- Testing
- M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW
- Where
- 16 sites in United States, Netherlands and 2 more
- Volunteers
- 97 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neoplasms
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
- Trial name
- NCT03416816
- Testing
- DSP-0337
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sumitomo Pharma America, Inc.
Motion Sickness
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample.
- Trial name
- NCT02155309
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Alzheimer's Disease
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
Primary Objective: To assess the safety and tolerability of escalating single and multiple doses of SAR228810 in patients with Alzheimer's disease (AD) Secondary Objective: To evaluate the pharmacokinetic properties of SAR228810…
- Trial name
- NCT01485302
- Testing
- SAR228810
- Where
- 8 sites in Bulgaria, France and 3 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Postmenopause
Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
The purpose of the study is to understand how bazedoxifene is absorbed in the body when it is given in combination with 2 different formulations of conjugated estrogens.
- Trial name
- NCT00479778
- Testing
- Bazedoxifene/conjugated estrogens
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer